Single Dose Crossover Comparative Bioavailability Study of Deferiprone 600 mg Delayed Release Tablets Versus Deferiprone Oral Solution in Healthy Male and Female Volunteers Following a 1200 mg Dose
Phase of Trial: Phase I
Latest Information Update: 15 May 2016
At a glance
- Drugs Deferiprone (Primary) ; Deferiprone
- Indications Iron overload; Pantothenate kinase-associated neurodegeneration
- Focus Pharmacokinetics
- Sponsors ApoPharma
- 14 Jul 2015 Status changed from recruiting to completed as reported byClinicalTrials.gov record.
- 26 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 15 May 2015 New trial record